- Conditions
- Constipation, Chronic Idiopathic Constipation, CIC
- Interventions
- BLI400 Laxative, BLI400 Placebo
- Drug
- Lead sponsor
- Braintree Laboratories
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,020 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 51
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 43 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1729–1752
of 7,464
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Childhood Cancer, Survivorship, Health Care Utilization, Health Knowledge, Attitudes, Practice, Adherence, Patient
- Interventions
- Multi-level Intervention of shared model of survivorship care, Comparison Group
- Behavioral · Other
- Lead sponsor
- Georgetown University
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 4
- States / cities
- Long Beach, California • Denver, Colorado • Hackensack, New Jersey + 1 more
- Conditions
- Breast Cancer, Metastatic Cancer, Pain, Prostate Cancer
- Interventions
- pain therapy, radiation therapy
- Procedure · Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 949 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 234
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 180 more
- Conditions
- Cystic Fibrosis
- Interventions
- CTX-4430, Placebo
- Drug
- Lead sponsor
- Celtaxsys, Inc.
- Other
- Eligibility
- 18 Years to 30 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 34 more
- Conditions
- Papulopustular Rosacea
- Interventions
- Azelaic acid, Vehicle foam
- Drug
- Lead sponsor
- LEO Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 7
- States / cities
- Denver, Colorado • Olathe, Kansas • Henderson, Nevada + 4 more
- Conditions
- Neoplasms
- Interventions
- Ris-Rez, Cisplatin, Carboplatin, Atezolizumab, Pembrolizumab, Durvalumab, Cetuximab, Bevacizumab, Tarlatamab, Dostarlimab
- Biological · Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 845 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 15
- States / cities
- Stanford, California • Denver, Colorado • New Haven, Connecticut + 12 more
- Conditions
- HIV Infections
- Interventions
- Pravastatin sodium, Simvastatin, Atorvastatin calcium, Ritonavir, Nelfinavir mesylate, Saquinavir
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Ends 2002
- U.S. locations
- 13
- States / cities
- Los Angeles, California • San Francisco, California • Stanford, California + 10 more
- Conditions
- Diabetes Mellitus
- Interventions
- Pramlintide
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 20 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Endometrial Cancer, Endometrial Cancer Recurrent, Lung Cancer Recurrent, Lung Cancer, Non-small Cell Lung Cancer Metastatic, Non-small Cell Carcinoma
- Interventions
- RGX-104, Ipilimumab, Docetaxel, Pembrolizumab, Carboplatin, Pemetrexed
- Drug
- Lead sponsor
- Inspirna, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2025
- U.S. locations
- 21
- States / cities
- Tucson, Arizona • Los Angeles, California • Aurora, Colorado + 16 more
- Conditions
- Chronic Constipation, Irritable Bowel Syndrome With Constipation
- Interventions
- Linaclotide
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,559 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 110
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 94 more
- Conditions
- Gram-negative Bacteremia
- Interventions
- Intravenous Antibiotics, Oral Antibiotics
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,030 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 11
- States / cities
- San Francisco, California • Denver, Colorado • Baltimore, Maryland + 7 more
- Conditions
- Gastric Cancer
- Interventions
- cisplatin, fluorouracil, leucovorin calcium, paclitaxel, surgery, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2011
- U.S. locations
- 30
- States / cities
- Denver, Colorado • Atlanta, Georgia • Chicago, Illinois + 23 more
- Conditions
- Recurrent Thyroid Cancer, Stage IVA Follicular Thyroid Cancer, Stage IVA Papillary Thyroid Cancer, Stage IVB Follicular Thyroid Cancer, Stage IVB Papillary Thyroid Cancer, Stage IVC Follicular Thyroid Cancer, Stage IVC Papillary Thyroid Cancer
- Interventions
- Decitabine, Iodine I 131, Recombinant thyrotropin alfa, Fludeoxyglucose F 18, Positron emission tomography
- Drug · Radiation · Biological + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2014
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Columbus, Ohio • Houston, Texas
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Dapagliflozin, Placebo for dapagliflozin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 833 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 36
- States / cities
- Little Rock, Arkansas • Encino, California • La Mesa, California + 33 more
- Conditions
- Infection, Human Immunodeficiency Virus, HIV Infections
- Interventions
- CAB Oral Tablets, CAB LA, ABC/3TC Oral tablets, RPV Oral Tablets, HAART, RPV
- Drug · Other
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 309 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2023
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 12 more
- Conditions
- Effusion Joint
- Interventions
- Arthrocentesis
- Procedure
- Lead sponsor
- Colorado Joint Replacement
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2024
- U.S. locations
- 2
- States / cities
- Aurora, Colorado • Denver, Colorado
- Conditions
- IgA Nephropathy, Immunoglobulin A Nephropathy
- Interventions
- BION-1301, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 383 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 28
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • San Francisco, California + 24 more
- Conditions
- Cystic Fibrosis
- Interventions
- VX-661/Ivacaftor, Ivacaftor, Placebo matched to VX-661/ ivacaftor, Placebo matched to Ivacaftor
- Drug
- Lead sponsor
- Vertex Pharmaceuticals Incorporated
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 248 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 44 more
- Conditions
- Chronic Myeloid Leukemia
- Interventions
- AMN107
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 59
- States / cities
- Mobile, Alabama • Tucson, Arizona • Duarte, California + 48 more
- Conditions
- Advanced Hepatocellular Carcinoma
- Interventions
- Oprozomib, Sorafenib
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 6
- States / cities
- Burlington, California • Denver, Colorado • Miami, Florida + 3 more
- Conditions
- Major Depressive Disorder
- Interventions
- ALTO-300, Placebo
- Drug
- Lead sponsor
- Alto Neuroscience
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 325 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 75
- States / cities
- Phoenix, Arizona • Yuma, Arizona • Rogers, Arkansas + 64 more
- Conditions
- Advanced NSCLC, Metastatic Lung Cancer
- Interventions
- Adagrasib oral dose of 400 mg twice daily tablets, Pembrolizumab, Chemotherapy: Pemetrexed, Cisplatin/Carboplatin
- Drug · Combination Product
- Lead sponsor
- Mirati Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 59
- States / cities
- Fountain Valley, California • Fullerton, California • San Francisco, California + 45 more
- Conditions
- Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma
- Interventions
- Cisplatin, Computed Tomography, Doxorubicin Hydrochloride, Doxorubicin-Eluting Beads, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Mitomycin, Pharmacological Study, Placebo Administration, Sorafenib Tosylate
- Drug · Procedure · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 235 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2022
- U.S. locations
- 281
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 183 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Baricitinib, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,877 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 67
- States / cities
- Glendale, Arizona • Mesa, Arizona • Peoria, Arizona + 58 more